Biotechnology
Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform. HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical‑st...
2026-03-17 21:30
3465
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therap...
2026-03-17 20:00
6278
/C O R R E C T I O N -- Gesynta Pharma/
In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as incorrectly transmitted by PR Newswire. The complete, cor...
2026-03-17 17:24
7707
Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleo...
2026-03-17 11:00
5924
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) tar...
2026-03-17 10:32
6196
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd
2026-03-17 09:05
4658
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
SHANGHAI, March 16, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK)optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of n...
2026-03-17 09:00
3202
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance * Revenue: US$959.5 million, +61.4% year-on-year * Gross profit: US$553.2 million, +103.3% year-on-year * Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance * GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ...
2026-03-16 18:54
6157
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (N...
2026-03-16 10:05
6606
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®[1], Floret...
2026-03-16 05:26
4998
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
* Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies * This partnership will generate revenue through: * A computational longevity platform, including unique curated datasets and accelerated computation methods releva...
2026-03-13 23:40
7506
BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
* BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. * The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU,China, March 13, 2026 /PRN...
2026-03-13 21:00
6753
Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthro...
2026-03-13 20:06
4002
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
* VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor * Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD * VIS-101 demonstrated mean BVCA improvements of >10 ETDRS let...
2026-03-13 18:05
6806
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excelle...
2026-03-13 11:09
4615
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially...
2026-03-13 09:53
5836
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — TOKYO, March 12, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboratio...
2026-03-13 08:00
3310
Emerald Clinical Trials Honored with 2026 Asia Pacific Biopharma Excellence Award for Outstanding Patient Recruitment & Engagement
SINGAPORE, March 12, 2026 /PRNewswire/ -- Emerald Clinical Trials
2026-03-12 21:02
3816
ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
* Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform * Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. , a biopharmaceutical company developing treatments...
2026-03-12 16:58
4585
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub
Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion. DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- GenScript announced the official opening of its first European mRNA production site in Delft, the ...
2026-03-12 15:11
3927
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
6049
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
6044
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
5933
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5886
